1
|
Gathe J, Arribas JR, Van Lunzen J, Garner W, Speck RM, Bender R, Shreay S, Nguyen T. Patient-Reported Symptoms over 48 Weeks in a Randomized, Open-Label, Phase 3b Non-inferiority Trial of Adults with HIV Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF Versus Continuation of Ritonavir-Boosted Protease Inhibitor with Emtricitabine and Tenofovir DF. Patient 2016; 8:445-54. [PMID: 26286337 PMCID: PMC4575373 DOI: 10.1007/s40271-015-0137-9] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
Background Coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate (EVG/COBI/FTC/TDF; Stribild®) is a recommended integrase inhibitor-based regimen in treatment guidelines from the US Department of Health and Human Services and the British HIV Association. The purpose of this analysis was to determine the change in patient-reported symptoms over time among HIV-infected adults who switch to Stribild® versus those continuing on a protease inhibitor (PI) with FTC/TDF. Methods A secondary analysis was conducted on the STRATEGY-PI study (GS-US-236-0115, ClinicalTrials.gov NCT01475838), a randomized, open-label, phase 3b trial of HIV-infected adults taking a PI with FTC/TDF who were randomly assigned (2:1) either to Stribild® (switch) or continuation of their existing regimen (no-switch). Logistic regressions and longitudinal modeling were conducted to evaluate the relationship of treatment with bothersome symptoms. Results At week 4 as compared with baseline, the switch group experienced a statistically significantly lower prevalence in five symptoms (diarrhea/loose bowels, bloating/pain/gas in stomach, pain/numbness/tingling in hands/feet, nervous/anxious, and trouble remembering). The lower prevalence of diarrhea/loose bowels, bloating/pain/gas in stomach, and pain/numbness/tingling in hands/feet observed at week 4 was maintained over time. While there were no significant differences between groups in the prevalence of sad/down/depressed and problems with sex at week 4 or week 48, longitudinal models indicated the switch group had a statistically significantly decreased prevalence in both symptoms from week 4 to week 48. As compared with the no-switch group, higher levels of satisfaction with treatment were experienced by patients in the switch group at the first follow-up visit and at week 24. Conclusions In this study sample, a switch from a ritonavir-boosted PI, FTC, and TDF regimen to coformulated EVG/COBI/FTC/TDF was associated with more treatment satisfaction and a reduction in the prevalence of patient-reported diarrhea/loose bowel symptoms, which was maintained over the 48-week study period. Electronic supplementary material The online version of this article (doi:10.1007/s40271-015-0137-9) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
| | | | - Jan Van Lunzen
- Universitaetsklinikum Hamburg-Eppendorf, Hamburg, Germany
| | - Will Garner
- Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA, 94404, USA
| | | | | | - Sanatan Shreay
- Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA, 94404, USA
| | - Thai Nguyen
- Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA, 94404, USA.
| |
Collapse
|
2
|
Mills A, Arribas JR, Andrade-Villanueva J, DiPerri G, Van Lunzen J, Koenig E, Elion R, Cavassini M, Madruga JV, Brunetta J, Shamblaw D, DeJesus E, Orkin C, Wohl DA, Brar I, Stephens JL, Girard PM, Huhn G, Plummer A, Liu YP, Cheng AK, McCallister S. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study. The Lancet Infectious Diseases 2016; 16:43-52. [DOI: 10.1016/s1473-3099(15)00348-5] [Citation(s) in RCA: 193] [Impact Index Per Article: 24.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/17/2015] [Revised: 08/25/2015] [Accepted: 09/14/2015] [Indexed: 10/22/2022]
|
3
|
Van Lunzen J. Gene therapy and bone marrow transplantation. BMC Infect Dis 2014. [PMCID: PMC4221066 DOI: 10.1186/1471-2334-14-s2-s19] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
4
|
Zoufaly A, Cozzi-Lepri A, Reekie J, Kirk O, Lundgren J, Reiss P, Jevtovic D, Machala L, Zangerle R, Mocroft A, Van Lunzen J. Immuno-virological discordance and the risk of non-AIDS and AIDS events in a large observational cohort of HIV-patients in Europe. PLoS One 2014; 9:e87160. [PMID: 24498036 PMCID: PMC3909048 DOI: 10.1371/journal.pone.0087160] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2013] [Accepted: 12/19/2013] [Indexed: 11/18/2022] Open
Abstract
BACKGROUND The impact of immunosuppression despite virological suppression (immuno-virological discordance, ID) on the risk of developing fatal and non-fatal AIDS/non-AIDS events is unclear and remains to be elucidated. METHODS Patients in EuroSIDA starting at least 1 new antiretroviral drug with CD4<350 cells/µl and viral load (VL)>500 copies/mL were followed-up from the first day of VL< = 50 copies/ml until a new fatal/non-fatal non-AIDS/AIDS event. Considered non-AIDS events included non-AIDS malignancies, pancreatitis, severe liver disease with hepatic encephalopathy (>grade 3), cardio- and cerebrovascular events, and end-stage renal disease. Patients were classified over time according to whether current CD4 count was above (non-ID) or below (ID) baseline level. Relative rates (RR) of events were calculated for ID vs. non-ID using adjusted Poisson regression models. RESULTS 2,913 patients contributed 11,491 person-years for the analysis of non-AIDS. 241 pre-specified non-AIDS events (including 84 deaths) and 89 AIDS events (including 10 deaths) occurred. The RR of developing pre-specified non-AIDS events for ID vs. non-ID was 1.96 (95% CI 1.37-2.81, p<0.001) in unadjusted analysis and 1.43 (0.94-2.17, p = 0.095) after controlling for current CD4 count. ID was not associated with the risk of AIDS events (aRR 0.76, 95% CI 0.41-1.38, p = 0.361). CONCLUSION Compared to CD4 responders, patients with immuno-virological discordance may be at increased risk of developing non-AIDS events. Further studies are warranted to establish whether in patients with ID, strategies to directly modify CD4 count response may be needed besides the use of ART.
Collapse
Affiliation(s)
- Alexander Zoufaly
- Department of Medicine I, Infectious Diseases Unit, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
- * E-mail:
| | - Alessandro Cozzi-Lepri
- Department of Infection and Population Health, University College London, London, United Kingdom
| | - Joanne Reekie
- Department of Infection and Population Health, University College London, London, United Kingdom
| | - Ole Kirk
- Copenhagen HIV Programme - Department of Infectious Diseases and Rheumatology, section 8632, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
| | - Jens Lundgren
- Copenhagen HIV Programme - Department of Infectious Diseases and Rheumatology, section 8632, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
| | - Peter Reiss
- University of Amsterdam, Academic Medical Center, Department of Global Health, and Stichting HIV Monitoring, Amsterdam, Netherlands
| | - Djordje Jevtovic
- University of Belgrade School of Medicine Infectious Diseases Hospital, HIV/AIDS Department, Belgrade, Serbia
| | - Ladislav Machala
- Department of Infectious Diseases, Third Faculty of Medicine, Charles University Prague, Prague, Czech Republic
| | - Robert Zangerle
- Medical University of Innsbruck, Department of Dermatology and Venereal Diseases, Innsbruck, Austria
| | - Amanda Mocroft
- Department of Infection and Population Health, University College London, London, United Kingdom
| | - Jan Van Lunzen
- Department of Medicine I, Infectious Diseases Unit, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| |
Collapse
|
5
|
Harrer T, Plettenberg A, Arastéh K, Van Lunzen J, Fätkenheuer G, Jaeger H, Janssens M, Burny W, Collard A, Roman F, Loeliger A, Koutsoukos M, Bourguignon P, Lavreys L, Voss G. Safety and immunogenicity of an adjuvanted protein therapeutic HIV-1 vaccine in subjects with HIV-1 infection: a randomised placebo-controlled study. Vaccine 2013; 32:2657-65. [PMID: 24144472 DOI: 10.1016/j.vaccine.2013.10.030] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2013] [Revised: 08/18/2013] [Accepted: 10/08/2013] [Indexed: 12/24/2022]
Abstract
The human immunodeficiency virus type-1 (HIV-1) vaccine candidate F4/AS01 has previously been shown to induce potent and persistent polyfunctional CD4(+) T-cell responses in HIV-1-seronegative volunteers. This placebo-controlled study evaluated two doses of F4/AS01 1-month apart in antiretroviral treatment (ART)-experienced and ART-naïve HIV-1-infected subjects (1:1 randomisation in each cohort). Safety, HIV-1-specific CD4(+) and CD8(+) T-cell responses, absolute CD4(+) T-cell counts and HIV-1 viral load were monitored for 12 months post-vaccination. Reactogenicity was clinically acceptable and no vaccine-related serious adverse events were reported. The frequency of HIV-1-specific CD4(+) T-cells 2 weeks post-dose 2 was significantly higher in the vaccine group than in the placebo group in both cohorts (p<0.05). Vaccine-induced HIV-1-specific CD4(+) T-cells exhibited a polyfunctional phenotype, expressing at least CD40L and IL-2. No increase in HIV-1-specific CD8(+) T-cells or change in CD8(+) T-cell activation marker expression profile was detected. Absolute CD4(+) T-cell counts were variable over time in both cohorts. Viral load remained suppressed in ART-experienced subjects. In ART-naïve subjects, a transient reduction in viral load from baseline was observed 2 weeks after the second F4/AS01 dose, which was concurrent with a higher frequency of HIV-1-specific CD4(+) T-cells expressing at least IL-2 in this cohort. In conclusion, F4/AS01 showed a clinically acceptable reactogenicity and safety profile, and induced polyfunctional HIV-1-specific CD4(+) T-cell responses in ART-experienced and ART-naïve subjects. These findings support further clinical investigation of F4/AS01 as a potential HIV-1 vaccine for therapeutic use in individuals with HIV-1 infection.
Collapse
Affiliation(s)
- Thomas Harrer
- Department of Internal Medicine III, University Hospital Erlangen, Friedrich-Alexander-University of Erlangen-Nuremberg, Ulmenweg 18, 91054 Erlangen, Germany.
| | - Andreas Plettenberg
- ifi-Institut für interdisziplinäre Medizin/Haus K, Asklepios Klinik St. Georg, Lohmühlenstr. 5, 20099 Hamburg, Germany.
| | - Keikawus Arastéh
- EPIMED/Vivantes Auguste-Viktoria-Klinikum, Rubensstr. 125, 12157 Berlin, Germany.
| | - Jan Van Lunzen
- Infectious Diseases Unit, University Medical Centre, Hamburg-Eppendorf, Martinistr. 52, 20246 Hamburg, Germany.
| | - Gerd Fätkenheuer
- Klinik I für Innere Medizin, University of Cologne, Kerpener Str. 62, 50937 Cologne, Germany.
| | - Hans Jaeger
- MUC Research GmbH, Karlsplatz 8, 80335 Munich, Germany.
| | - Michel Janssens
- GlaxoSmithKline Vaccines, Rue de l'Institut 89, 1345 Rixensart, Belgium.
| | - Wivine Burny
- GlaxoSmithKline Vaccines, Rue de l'Institut 89, 1345 Rixensart, Belgium.
| | - Alix Collard
- GlaxoSmithKline Vaccines, Rue de l'Institut 89, 1345 Rixensart, Belgium.
| | - François Roman
- GlaxoSmithKline Vaccines, Rue de l'Institut 89, 1345 Rixensart, Belgium.
| | - Alfred Loeliger
- GlaxoSmithKline Vaccines, Rue de l'Institut 89, 1345 Rixensart, Belgium.
| | | | | | - Ludo Lavreys
- GlaxoSmithKline Vaccines, Rue de l'Institut 89, 1345 Rixensart, Belgium.
| | - Gerald Voss
- GlaxoSmithKline Vaccines, Rue de l'Institut 89, 1345 Rixensart, Belgium.
| |
Collapse
|
6
|
Rodger AJ, Bruun T, Vernazza P, Collins S, Estrada V, Van Lunzen J, Corbelli GM, Phillips AN, Lundgren JD. Further research needed to support a policy of antiretroviral therapy as an HIV prevention initiative. Antivir Ther 2013; 18:285-7. [PMID: 23615792 DOI: 10.3851/imp2609] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/29/2012] [Indexed: 10/26/2022]
Abstract
The results from the HPTN 052 trial have increased the focus on use of antiretroviral therapy (ART) for prevention of HIV transmission; however, condom use also effectively prevents HIV transmission. Studies in heterosexual serodiscordant couples with viral suppression have so far only reported follow-up data for 330 couple-years when condoms were not being used. Data are even more limited for anal sex in men who have sex with men. Additional data on the effectiveness of ART as prevention when practicing condom-less sex is urgently needed.
Collapse
|
7
|
Rodger A, Bruun T, Weait M, Vernazza P, Collins S, Estrada V, Lunzen JV, Corbelli GM, Lampe F, Phillips A, Lundgren J. Partners of people on ART - a New Evaluation of the Risks (The PARTNER study): design and methods. BMC Public Health 2012; 12:296. [PMID: 22520171 PMCID: PMC3382424 DOI: 10.1186/1471-2458-12-296] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2012] [Accepted: 04/20/2012] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND It is known that being on antiretroviral therapy reduces the risk of HIV transmission through sex. However it remains unknown what the absolute level of risk of transmission is in a person on ART with most recent measured HIV plasma viral load<50 c/mL in the absence of condom use. There are no data on risk of transmission for anal sex in MSM when the index partner is on ART. METHODS/DESIGN The PARTNER study is an international, observational multi-centre study, taking place from 2010 to 2014 in which HIV serodifferent partnerships who at enrolment reported recently having had condom-less vaginal or anal sexual intercourse are followed over time, with 46 monthly reporting of transmission risk behaviour through a confidential self completed risk behaviour questionnaire and with 46 monthly HIV testing for the HIV negative partner. The objective is to study (i) the risk of HIV transmission to partners, in particular in partnerships that continue not to use condoms consistently and the HIV-positive partner is on therapy with a viral load<50 copies/mL and (ii) why some partnerships do not use condoms, to describe the proportion who begin to adopt consistent condom use, and factors associated with this. For any negative partner who becomes infected phylogenetic analysis will be used following anonymisation of the samples to assess if transmission had been from the HIV infected partner. DISCUSSION This observational study will provide missing information on the absolute risk of HIV transmission for both vaginal and anal sex when the index case is on ART with a VL<50 copies/mL in the absence of condom use.
Collapse
Affiliation(s)
- Alison Rodger
- Research Department of Infection & Population Health, University College London, London, UK.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Hoffmann C, Wolf E, Wyen C, Fätkenheuer G, Van Lunzen J, Stellbrink HJ, Stoehr A, Plettenberg A, Jaeger H, Noppeney R, Hentrich M, Goekbuget N, Hoelzer D, Horst HA. AIDS-associated Burkitt or Burkitt-like lymphoma: Short intensive polychemotherapy is feasible and effective. Leuk Lymphoma 2009; 47:1872-80. [PMID: 17065000 DOI: 10.1080/10428190600685467] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
The objective was to evaluate the feasibility and efficacy of a short-term, multi-agent and dose intensive regimen in AIDS patients with Burkitt or Burkitt-like lymphoma (BL/BLL) and to compare its efficacy with that of a conventional regimen. This was a retrospective, multi-center cohort study of all HIV-1-infected patients diagnosed with BL/BLL between 1990 - 2004. Patients were assigned to two different chemotherapy approaches. Group A received a protocol which was adapted from the German multi-center study group for adult acute lymphoblastic leukemia (GMALL). Group B received a conventional CHOP-based chemotherapy. Fifty-one patients were included in the analysis. In group A (n = 20), significantly more patients achieved complete remission (75% vs 40%, P = 0.02) than in group B (n = 31). One-year survival in group A was 65% compared to 44% in group B (P = 0.17). In a multi-variable Cox regression analysis, treatment according to the GMALL protocol was significantly associated with prolonged survival with a relative hazard rate of 0.13 (95% CI 0.03 - 0.63, P = 0.01). In conclusion, the short and intensive GMALL protocol for B-ALL/NHL is feasible in patients with AIDS-BL/BLL. Outcome may be improved compared to patients treated with CHOP-based regimens. In the era of HAART, more intensive chemotherapy regimens should be considered in patients with highly aggressive lymphomas.
Collapse
|
9
|
Degen O, Van Lunzen J, Stellbrink HJ. Intensification of Background Antiretroviral Therapy with Abacavir during Low-Level Failure May Restore Optimal Suppression. Antivir Ther 2000. [DOI: 10.1177/135965350000500204] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Objective To investigate the antiviral activity of abacavir added to stable background therapy. Design: Retrospective analysis. Materials and Methods In 27 subjects with detectable plasma viraemia during stable treatment abacavir was added as the only agent. Patients were pre-treated for 180 weeks (mean) with regimens containing zidovudine (102 weeks) and lamivudine (88 weeks). Results were analysed in two groups: group 1, >400 HIV RNA copies/ml; group 2, 25–399 copies/ml. In 7/13 group 1 patients genotypic resistance analysis was performed prior to abacavir. Results Median follow-up was 28 weeks, median HIV RNA load at baseline 2.48 log10 copies/ml (3.52 and 1.66 log10 copies/ml in groups 1 and 2, respectively). Plasma viraemia was reduced to less than 400 HIV RNA copies/ml in 2/13 subjects in group 1 and 11/11 in group 2 (week 24). Only one patient in group 1 responded transiently to less than 25 HIV RNA copies/ml. In contrast, 10/14 and 11/11 in group 2 reached values below this threshold at weeks 12 and 24, respectively. Overall, 7/13 group 1 patients were found with ≥2 zidovudine resistance-associated mutations. The lamivudine resistance-associated mutation M184V was present in four of seven cases. All of these patients showed only a moderate and transient reduction of plasma viraemia (medium peak reduction of 0.73 log10 after 20 weeks). Conclusions The addition of abacavir during low-level treatment failure may restore or achieve suppression to levels below the cut-off of the ultrasensitive PCR.
Collapse
Affiliation(s)
- Olaf Degen
- Medizinische Kernklinik und Poliklinik, Universitätskrankenhaus Eppendorf, Hamburg, Germany
| | - Jan Van Lunzen
- Medizinische Kernklinik und Poliklinik, Universitätskrankenhaus Eppendorf, Hamburg, Germany
| | - Hans-Jürgen Stellbrink
- Medizinische Kernklinik und Poliklinik, Universitätskrankenhaus Eppendorf, Hamburg, Germany
| |
Collapse
|